Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 67
- 试验地点
- 1
- 主要终点
- Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients
研究概览
简要总结
Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce "oxidative stress". It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •CKD stage 3
排除标准
- •Known heart failure
- •Patients already on Allopurinol
- •Patients with gout
- •Patients with hepatic disease
- •Contraindications to MRI, including severe claustrophobia
- •Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine
- •Malignancy or other life threatening disease
- •Pregnancy or lactating women
- •Patients unable to provide written consent
研究组 & 干预措施
I
CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
干预措施: Placebo (Drug)
2
干预措施: Allopurinol (Drug)
结局指标
主要结局
Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients
时间窗: 9 months
次要结局
- Secondary objective is to see if Allopurinol reduces endothelial dysfunction in this group of CKD patients(9 months)
研究者
A. D. Struthers
Head Of Cardiovascular and Diabetes Medicine
University of Dundee